- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06644066
Partial Pressure of Oxygen Control Method in Identification of Intersegmental Plane
January 5, 2025 updated by: Tang-Du Hospital
Application of Partial Pressure of Oxygen Control Method in Fast Identification of Intersegmental Plane in Anatomical Sublobar Resection: a Prospective, Randomized Controlled Study
In recent years, an increasing number of pulmonary nodules have been detected through CT screening.
The traditional surgical method for lung cancer is lobectomy combined with lymph node dissection.
However, recent studies have demonstrated that sublobar resection for early non-small cell lung cancer (NSCLC) is an effective alternative with the additional benefit of preserving more pulmonary function.
However, it also faces many problems, the most prominent of which is the rapid and accurate identification of the intersegmental plane (ISP) during surgery.
The modified inflation-deflation method for identifying the ISP is the most commonly used method in anatomical sublobar resection.
Nevertheless, the lengthy waiting periods and the lack of clear delineation represent significant challenges in clinical practice.
The Partial pressure of Oxygen Control method facilitates the efficient determination of the ISP by reducing the oxygen inhalation concentration and ventilator ventilation time during surgery.
This results in a reduced PaO2 in arterial blood, thereby accelerating the rapid appearance of the ISP.
Thus, the investigators conducted a prospective, randomized, controlled trial to ascertain whether the oxygen partial pressure control method affects the occurrence time of the ISP and PaO2 during one-lung ventilation, in comparison to the modified inflation-deflation method.
Furthermore, the objective was to confirm the safety and efficacy of Partial pressure of Oxygen Control method.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Mingliang Xing
- Phone Number: 15129745755
- Email: 312596733@QQ.COM
Study Contact Backup
- Name: Xiaolong Yan, MD
- Phone Number: 15991269383
- Email: yanxiaolong@fmmu.edu.cn
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710000
- Recruiting
- The Second Affiliated Hospital of the Air Force Medical University of PLA
-
Contact:
- Mingliang Xing
- Phone Number: 15129745755
- Email: 312596733@QQ.COM
-
Contact:
- Xiaolong Yan, MD
- Phone Number: 15991269383
- Email: yanxiaolong@fmmu.edu.cn
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Between the ages of 18 and 75;
- Gender unlimited;
- Eastern Cooperative Oncology Group(ECOG) Performance status(PS) score 0-1 points;
- Thin slice CT indicates that the maximum tumor diameter is ≤ 2.0cm and 0 ≤ CTR<1.0; (Consolidation Tumor Ratio,CTR)
- Those who voluntarily sign the informed consent form for research can comply with the requirements of the research visit plan and other protocols.
Exclusion Criteria:
- Individuals with a history of lung surgery in the past;
- Patients with interstitial pneumonia, pulmonary alveoli, pulmonary fibrosis, or severe emphysema;
- Those who undergo chest surgery due to various reasons or change the surgical plan during the operation;
- The subjects do not understand, cooperate or refuse to sign the informed consent form regarding the research protocol.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Partial pressure of Oxygen Control method
After the targeted structures were successfully dissected, the anesthesiologist manually controls pure oxygen one-lung ventilation on the surgical side until the lung is fully expand.
The ventilator is disconnected, the airway is opened, and the operator uses a gauze ball to pressure the preserve lung tissue.
At a SpO2 of 95%, the healthy side undergoes one-lung ventilation.
|
During the process of inflation-deflation, by maintaining a lower PaO2, the identifying the intersegmental plane is accelerated
|
|
No Intervention: Modified inflation-deflation method
After the targeted structures were successfully dissected, and then the collapsed lung was re-expanded completely with controlled airway pressure under 20 cmH2O, with the bronchus of the operation side open to atmosphere while continuing ventilation of the contralateral lung.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time of Intersegmental plane(TISP)
Time Frame: Throughout the entire surgical period,an average of 10 minutes
|
The start time was defined as the end of the surgical side lung having completely re-expanded.
The end point was identified as the point at which the preserved lung was fully deflated, and a boundary had formed between the targeted lung tissue and the reserved lung.
|
Throughout the entire surgical period,an average of 10 minutes
|
|
The lung collapse score
Time Frame: Throughout the entire surgical period
|
The lung collapse score was referenced and improved by the Bussiers method using descriptive and visual features that included the context of lung collapse, space in the thermal cavity, atelectasis, color of the lung (healthy lungs are a pink gray/simple color), and where the collapse was considered satisfactory.Lung collapse was defined on a 4-point scale, where 1 point int=no lung collapse, 2 point=less partial lung collapse, 3 point=major partial lung collapse, 4 point=total lung collapse Each video clip was assessed by 2 evaluators。 Independently evaluate the level, and resolve differences through consensus through negotiation.
|
Throughout the entire surgical period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Surgical time
Time Frame: Throughout the entire surgical period,An average of 120 minutes
|
The total time from the start of skin incision to the completion of chest closure
|
Throughout the entire surgical period,An average of 120 minutes
|
|
Blood gas analysis
Time Frame: Throughout the entire surgical period,Baseline, Up to 120 minutes
|
Blood gas analysis measuring before entry, after one lung ventilation (SpO2 maintained at 95%), after pure oxygen lung stimulation, and at 3 and 6 minutes after pure oxygen lung expand.
|
Throughout the entire surgical period,Baseline, Up to 120 minutes
|
|
Intraoperative bleeding volume
Time Frame: Throughout the entire surgical period
|
Intraoperative bleeding volume: Use a suction device and a graduated collection device to collect intraoperative bleeding volume in milliliters, accurate to ten digits.
(An average of 50ml)
|
Throughout the entire surgical period
|
|
Postoperative drainage volume
Time Frame: Intraoperative
|
Postoperative drainage volume: The total drainage volume in the drainage bottle during the retention of the thoracic catheter after surgery, in milliliters.
(An average of 200ml)
|
Intraoperative
|
|
Postoperative complication incidence
Time Frame: Throughout the perioperative period,Baseline, Up to 3 months
|
Postoperative complication incidence: Record the name of the complication and classify it according to the Clavien Indo classification system
|
Throughout the perioperative period,Baseline, Up to 3 months
|
|
Postoperative hospitalization days
Time Frame: From surgery to discharge ,An average of 5 days
|
The number of days between the surgical date and the discharge date;
|
From surgery to discharge ,An average of 5 days
|
|
Total hospitalization cost
Time Frame: Up to 3 months
|
Total hospitalization cost: The total cost of patients from admission to discharge, settled in ChiNaYuan(CNY) (before medical insurance settlement).
|
Up to 3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 1, 2024
Primary Completion (Actual)
July 30, 2024
Study Completion (Estimated)
December 30, 2024
Study Registration Dates
First Submitted
July 1, 2024
First Submitted That Met QC Criteria
October 15, 2024
First Posted (Actual)
October 16, 2024
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
January 5, 2025
Last Verified
January 1, 2025
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- K202406-24
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
Beth Israel Deaconess Medical CenterDana-Farber Cancer Institute; MedWaves, IncRecruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)TerminatedStage IV Lung Cancer | Stage III Lung Cancer | Stage I Lung Cancer | Stage II Lung CancerUnited States
Clinical Trials on Partial pressure of Oxygen Control method
-
Sahlgrenska University Hospital, SwedenGöteborg University; KTH Royal Institute of Technology; Swedish Armed Forces...CompletedInflammation | Central Nervous System Injury | Diving MedicineSweden
-
Inonu UniversityNot yet recruiting
-
Central Hospital, Nancy, FranceUniversity of Lorraine; Centre National de la Recherche Scientifique, FranceNot yet recruitingClinical Evaluation of an Innovative Non-contact Optical Device for Skin Oxygenation Imaging (IMOXY)Obliterating Arteriopathy of the Lower Limbs | Chronic WoundsFrance
-
Inonu UniversityCompletedMorbid Obesity | Bariatric Surgery Candidate | Hemodynamic InstabilityTurkey
-
Bo Wang,MDUnknownEndoscopy | Papillary Thyroid Carcinoma | Thyroid Cancer | ThyroidectomyChina
-
Washington State UniversityActive, not recruiting
-
VA Office of Research and DevelopmentRecruitingObstructive Sleep Apnea | OSA COPD Overlap SyndromeUnited States
-
Assiut UniversityUnknownCritical Illness | Intra-Abdominal Hypertension
-
Marshall HollandCompletedRestless Legs Syndrome | Neuropathic PainUnited States